Overview

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aromatase inhibitor letrozole) as a first or second line of therapy in patients with metastatic hormone receptor positive and HER2-positive breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Colorado, Denver

Collaborator:

Academic Breast Cancer Research Consortium (ABRCC)

Treatments:

Letrozole
Palbociclib
Tucatinib